EP1392231A2 - Utilisation d'electrolytes pour renforcer la fonction barriere de la peau - Google Patents

Utilisation d'electrolytes pour renforcer la fonction barriere de la peau

Info

Publication number
EP1392231A2
EP1392231A2 EP02743014A EP02743014A EP1392231A2 EP 1392231 A2 EP1392231 A2 EP 1392231A2 EP 02743014 A EP02743014 A EP 02743014A EP 02743014 A EP02743014 A EP 02743014A EP 1392231 A2 EP1392231 A2 EP 1392231A2
Authority
EP
European Patent Office
Prior art keywords
skin
preparations
acid
cosmetic
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02743014A
Other languages
German (de)
English (en)
Inventor
Thomas Döring
Volker Schreiner
Wilfrid Siefken
Gerhard Sauermann
Helga Biergiesser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beiersdorf AG
Original Assignee
Beiersdorf AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7684962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1392231(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Beiersdorf AG filed Critical Beiersdorf AG
Priority to EP09004241.7A priority Critical patent/EP2090283B1/fr
Publication of EP1392231A2 publication Critical patent/EP1392231A2/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/20—Halogens; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/86—Polyethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings

Definitions

  • the present invention relates to the use of electrolytes for the production of cosmetic or dermatological preparations for the treatment and prevention of dry skin and the use of electrolytes for the production of cosmetic and dermatological preparations for the treatment and prevention of dry skin and to strengthen the barrier function of the skin.
  • the skin is the largest human organ. Among its many functions (for example for heat regulation and as a sensory organ), the barrier function, the one that prevents the skin (and ultimately the entire organism) from drying out, is probably the most important. At the same time, the skin acts as a protective device against the penetration and absorption of substances coming from outside. This barrier function is brought about by the epidermis, which as the outermost layer forms the actual protective cover against the environment. At around a tenth of the total thickness, it is also the thinnest layer of the skin.
  • the epidermis is a stratified tissue in which the outer layer, the horny layer (stratum corneum), is the important part for the barrier function. It is worn out in contact with the environment and is therefore in a constant process of renewal, with fine scales being continuously released to the outside and corneal and lipid material horned from the inside being reproduced.
  • the skin model of Elias (PM Elias, Structure and Function of the Stratum Corneum Permeability Barrier, Drug Dev. Res. 13, 1988, 97-105), which is recognized by experts today, describes the horny layer as a two-component system, similar to a brick wall (Bricks and mortar model).
  • the homocytes (corneocytes) correspond to the bricks
  • the complex lipid membrane in the intercellular spaces corresponds to the mortar.
  • This system essentially represents a physical barrier against hydrophilic substances, but due to its narrow and multilayer structure it is equally difficult for lipophilic substances to pass through.
  • the special structure of the horny layer protects the skin on the one hand and on the other hand stabilizes its own flexibility by binding a defined amount of water.
  • the regulation of water and moisture content is one of the most important functions of the epidermal lipid membrane. However, it not only has a barrier effect against external chemical and physical influences, but also contributes to the cohesion of the horny layer.
  • the lipids of the horny layer essentially consist of ceramides, free fatty acids, cholesterol and cholesterol sulfate and are distributed over the entire horny layer.
  • the composition of these lipids is of crucial importance for the intact function of the epidermal barrier and thus for the water impermeability of the skin.
  • the skin's horny layer swells.
  • the degree of this swelling depends, among other things, on the duration of the bath and its temperature.
  • water-soluble substances are washed off or washed out, e.g. B. water-soluble dirt components, but also the skin's own substances, which are responsible for the water retention capacity of the horny layer.
  • Skin oils are also dissolved and washed out to a certain extent by the skin's own surface-active substances. After initial swelling, this causes the skin to subsequently dry out, which can be significantly enhanced by washing-active additives.
  • the barrier effect of the skin can be quantified by determining the transepidermal water loss (TEWL - transepidermal water loss). This is the evaporation of water from the inside of the body without taking into account the loss of water when sweating.
  • the determination of the TEWL value has proven to be extremely informative and can be used to diagnose cracked or chapped skin, to determine the compatibility of chemically differently structured surfactants and the like.
  • the water content in the top layer of skin is of the utmost importance. It can be influenced to a limited extent by introducing moisture regulators.
  • Anionic surfactants which are generally components of cleaning preparations, can increase the pH in the horny layer for a long time, which means regenerative processes that serve to restore and renew the barrier function of the skin. severely disabled. In this case, a new, often very unfavorable state of equilibrium occurs in the horny layer between regeneration and the loss of essential substances through regular extraction, which significantly affects the external appearance of the skin and the physiological functioning of the horny layer.
  • Skin care in the sense of the present invention is to be understood primarily as meaning that the natural function of the skin acts as a barrier against environmental influences (e.g. dirt, chemicals, microorganisms) and against the loss of the body's own substances (e.g. water, lipids, electrolytes). is strengthened or restored.
  • environmental influences e.g. dirt, chemicals, microorganisms
  • loss of the body's own substances e.g. water, lipids, electrolytes
  • the effect of ointments and creams on the barrier function and the hydration of the horny layer is based essentially on the covering (occlusion) of the treated skin areas.
  • the ointment or cream is, so to speak, a (second) artificial barrier that is supposed to prevent water loss from the skin.
  • This physical barrier can be removed correspondingly easily, for example with cleaning agents, as a result of which the original, impaired state is reached again.
  • the skin care effect can decrease with regular treatment. After stopping the application of the product, the skin quickly returns to the condition before the start of treatment. With certain products, the condition of the skin may even temporarily deteriorate. A sustainable product effect is therefore generally not achieved or only to a limited extent.
  • the effect of nourishing cleaning products essentially consists in an efficient regreasing with sebum lipid-like substances.
  • the change in the surfactant content of such preparations can further limit the damage to the horny layer barrier.
  • the prior art lacks preparations which positively influence the barrier function and the hydration of the horny layer and which strengthen or even restore the physicochemical properties of the horny layer and in particular of the lamellae made of intercellular lipids.
  • intercellular lipid mixtures such as ceramides or ceramide analogues, which are to be used by the skin to rebuild the natural barrier, have recently been increasingly added to the topical preparations.
  • these lipids are mostly very expensive raw materials. In addition, their effect is usually less than expected.
  • the object of the present invention was therefore to eliminate the disadvantages of the prior art.
  • skin care preparations should be made available that maintain or restore the skin's barrier properties, especially when the natural regeneration of the skin is not sufficient. They should also be suitable for the treatment and prophylaxis of consequential damage to skin drying out, for example fissures or inflammatory or allergic processes or also neurodermatitis. It was also an object of the present invention to provide stable skin-care cosmetic and / or dermatological agents which protect the skin from environmental influences such as sun and wind. In particular, the effect of the preparations should be physiological, quick and sustainable.
  • the present invention is advantageously implemented by using inorganic salts (in particular NaCl, NaBr, Nal, Na 2 B 4 O 7 , Na 2 SiO 3 , Na 2 CO 3 , NaHCO 3 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 , KCI, Kl, LiCI, NH 4 CI, ZnCI 2 , AI 2 SO 3 and MgSO) as well as salts of acids naturally occurring in the skin (e.g. energy metabolism such as sodium liponate, sodium citrate, ammonium lactate, sodium lactate, sodium bicarbonate, sodium citrate ) or weak carboxylic acids (eg sodium propionate) for the treatment and prevention of dry skin.
  • inorganic salts in particular NaCl, NaBr, Nal, Na 2 B 4 O 7 , Na 2 SiO 3 , Na 2 CO 3 , NaHCO 3 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 , KCI, Kl, LiCI,
  • the active system mentioned stimulates the skin's own metabolism of lipids and proteins, which have to be constantly re-formed in order to maintain the epidermal barrier for water.
  • the dry skin is treated and / or cared for by the barrier-strengthening effect of these preparations, while actively drying out normal skin.
  • Cosmetic or dermatological preparations according to the invention preferably contain 0.05-30% by weight, particularly preferably 1-5% by weight, of one or more electrolytes, preferably sodium chloride, based on the total composition of the preparations.
  • Glycerol is advantageous - although not mandatory - in cosmetic or dermatological preparations according to the invention preferably at 0.05% by weight to 30% by weight, preferably at 0.1% by weight to 20% by weight, particularly preferably 1 - 15 wt .-%, based on the total weight of the preparations.
  • the cosmetic or dermatological preparations according to the invention can be composed as usual and can be used for the treatment, care and cleaning of the skin and / or hair and as a make-up product in decorative cosmetics.
  • they can be used, for example, as skin protection cream, cleansing milk, sunscreen lotion, nutritional cream, day or night cream, etc. It may be possible and advantageous to use the preparations according to the invention as the basis for pharmaceutical formulations.
  • the active ingredient combinations used according to the invention are particularly preferably used in pH-buffered preparations, a pH range of 5-7, in particular about 5-6, being very particularly preferred.
  • Cosmetic and dermatological preparations which are in the form of a sunscreen are also favorable.
  • these preferably contain at least one UV-A filter substance and / or at least one UV-B filter substance and / or at least one inorganic pigment.
  • cosmetic and dermatological preparations whose main purpose is not protection against sunlight, but which nevertheless contain UV protection substances.
  • UV-A or UV-B filter substances are usually incorporated into day creams.
  • the cosmetic and dermatological preparations according to the invention can contain cosmetic auxiliaries as are usually used in such preparations, for example preservatives, bactericides, perfumes, substances for preventing foaming, dyes, pigments which have a coloring effect, thickeners, surface-active substances, emulsifiers, softening, moisturizing and / or moisturizing substances, fats, oils, waxes or other usual components of a cosmetic or dermatological formulation such as alcohols, polyols, polymers, foam stabilizers, organic solvents or silicone derivatives.
  • Preparations for the treatment and care of the skin are particularly preferred.
  • the cosmetic and dermatological preparations according to the invention are applied to the skin and / or the hair in a sufficient amount in the manner customary for cosmetics.
  • Cosmetic and dermatological preparations according to the invention can be in various forms. So you can z. B. a solution, an anhydrous preparation, an emulsion or microemulsion of the water-in-oil (W / O) or oil-in-water (O / W) type, a multiple emulsions, for example of the water-in-oil type in water (W / O / W), a gel, a solid stick, an ointment or an aerosol. It is also advantageous to present the active compounds according to the invention in encapsulated form, e.g. in collagen matrices and other common encapsulation materials, e.g. as cellulose encapsulation, encapsulated in gelatin, wax matrices or liposomal.
  • encapsulated form e.g. in collagen matrices and other common encapsulation materials, e.g. as cellulose encapsulation, encapsulated in gelatin, wax matrices or liposomal.
  • the cosmetic and dermatological preparations according to the invention can also contain antioxidants.
  • antioxidants favorable antioxidants dantien all antioxidants suitable or customary for cosmetic and / or dermatological applications are used.
  • the antioxidants are advantageously selected from the group consisting of amino acids (e.g. glycine, histidine, tyrosine, tryptophan) and their derivatives, imidazoles (e.g. urocanic acid) and their derivatives, peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anserine), carotenoids, carotenes (e.g. ⁇ -carotene, ß-carotene, ⁇ -lycopene) and their derivatives, chlorogenic acid and its derivatives, lipoic acid and its Derivatives (e.g.
  • amino acids e.g. glycine, histidine, tyrosine, tryptophan
  • imidazoles e.g. urocanic acid
  • peptides such as D, L-carnosine, D-carnosine, L-carnosine and their derivatives (e.g. anser
  • thiols e.g. thioredoxin, glutathione, cysteine, cystine, cystamine and their glycosyl, N-acetyl, methyl, ethyl, propyl, Amyl, butyl and lauryl, palmitoyl, oleyl, ⁇ -unoleyl, cholesteryl and glyceryl esters
  • salts dilauryl thiodipropionate, distearyl thiodipropionate, thiodipropionic acid and their derivatives (esters, ethers, peptides, lipids, nucleotides, nucleosides and Salts) and sulfoximine compounds (e.g.
  • buthionine sulfoximines in very low tolerable doses (e.g. B. pmol to ⁇ mol / kg), furthermore (metal) chelators (eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin), ⁇ -hydroxy acids (eg citric acid, lactic acid, malic acid), humic acid, Bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g.
  • metal chelators eg ⁇ -hydroxy fatty acids, palmitic acid, phytic acid, lactoferrin
  • ⁇ -hydroxy acids eg citric acid, lactic acid, malic acid
  • humic acid Bile acid, bile extracts, bilirubin, biliverdin, EDTA, EGTA and their derivatives, unsaturated fatty acids and their derivatives (e.g
  • ⁇ -linolenic acid linoleic acid, oleic acid
  • folic acid and their derivatives ubiquinone and ubiquinol and their derivatives
  • vitamin C and derivatives e.g. ascorbyl palmitate, Mg ascorbyl phosphate, ascorbyl acetate
  • tocopherols and derivatives e.g.
  • vitamin E acetate
  • vitamin A and derivatives vitamin A palmitate
  • coniferyl benzoate of benzoin, rutinic acid and the like Derivatives, ⁇ -glycosylrutin, ferric acid, furfurylidene glucitol, camosin, butylated hydroxytoluene, butylated hydroxyanisole, nordic hydroguajak resin acid, nordihydroguajaretic acid, trihydroxybutyrophenone, uric acid and its derivatives, mannose and their derivatives, zinc and its derivatives (z O), selenium and its derivatives (e.g. B.
  • stilbenes and their derivatives for example stilbene oxide, trans-stilbene oxide
  • derivatives suitable according to the invention salts, esters, ethers, sugars, nucleotides, nucleosides, peptides and lipids
  • the amount of the aforementioned antioxidants (one or more compounds) in the preparations according to the invention is preferably 0.001 to 30% by weight, particularly preferably 0.05-20% by weight, in particular 1-10% by weight, based on the total weight of the preparation.
  • vitamin E and / or its derivatives represent the antioxidant (s)
  • vitamin A or vitamin A derivatives or carotenes or their derivatives represent the antioxidant or antioxidants, it is advantageous to have their respective concentrations in the range from 0.001-10% by weight, based on the total weight of the formulation, to choose.
  • Emulsions according to the invention are advantageous and contain e.g. the fats, oils, waxes and other fat bodies mentioned, as well as water and an emulsifier, as is usually used for such a type of formulation.
  • the lipid phase can advantageously be selected from the following group of substances: mineral oils, mineral waxes
  • Oils such as triglycerides of capric or caprylic acid as well as natural oils such as e.g. Castor oil;
  • Fats, waxes and other natural and synthetic fat bodies preferably esters of fatty acids with alcohols of low C number, e.g. with isopropanol, propylene glycol or glycerin, or esters of fatty alcohols with low C number alkanoic acids or with fatty acids; benzoates;
  • Silicone oils such as dimethylpolysiloxanes, diethylpolysiloxanes, diphenylpolysiloxanes and mixed forms thereof.
  • the oil phase of the emulsions, oleogels or hydrodispersions or lipodispersions for the purposes of the present invention is advantageously selected from the group of esters from saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 3 to 30 carbon atoms and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C atoms, from the group of esters from aromatic carboxylic acids and saturated and / or unsaturated, branched and / or unbranched alcohols with a chain length of 3 to 30 C- Atoms.
  • ester oils can then advantageously be selected from the group of isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononylisononanoate, 2-ethylhexyl, ethyl-2-ethylhexyl, ethyl-2-ethylhexyl 2-octyldodecyl palmitate, oleyl oleate, olerlerucate, erucyl oleate, erucylerucate and synthetic, semi-synthetic and natural mixtures of such esters, for example jojoba oil.
  • the oil phase can advantageously be selected from the group of branched and unbranched hydrocarbons and waxes, the silicone oils, the dialkyl ethers, the group of saturated or unsaturated, branched or unbranched alcohols, and also the fatty acid triglycerides, especially the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkane carboxylic acids with a chain length of 8 to 24, in particular 12 - 18 carbon atoms.
  • the fatty acid triglycerides can, for example, advantageously be selected from the group of synthetic, semisynthetic and natural oils, e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil and the like.
  • any mixtures of such oil and wax components can also be used advantageously for the purposes of the present invention. It may also be advantageous to use waxes, for example cetyl palmitate, as the sole lipid component of the oil phase.
  • the oil phase is selected from the group 2-ethylhexyl advantageous, octyldodecanol, isotridecyl isononanoate, isoeicosane, 2-ethylhexyl cocoate, C, 2 .. 5 alkyl benzoate, caprylic capric acid triglyceride, dicaprylyl ether.
  • Particularly advantageous are mixtures of C 12-15 -alkyl benzoate and 2-ethylhexyl isostearate, mixtures of 2- C ⁇ ⁇ 5 alkyl benzoate and isotridecyl isononanoate and mixtures of C. 2- 15 alkyl benzoate, 2-ethylhexyl isostearate and isotridecyl isononanoate.
  • paraffin oil paraffin oil
  • squalane and squalene can be used advantageously for the purposes of the present invention.
  • the oil phase can advantageously also contain cyclic or linear silicone oils or consist entirely of such oils, although it is preferred to use an additional content of other oil phase components in addition to the silicone oil or the silicone oils.
  • Cyclomethicone (octamethylcyclotetrasiloxane) is advantageously used as the silicone oil to be used according to the invention.
  • other silicone oils can also be used advantageously for the purposes of the present invention, for example hexamethyicyclotrisiloxane, polydimethylsiloxane, poly (methylphenylsiloxane).
  • Advantageous emulsifiers are, for example, glyceryl stearate in a mixture with ceteareth-20; sorbitan; sorbitan; Ceteareth-25; Ceteareth-6 in a mixture with stearyl alcohol; Cetylstearyl alcohol mixed with PEG-40 castor oil and sodium cetylstearyl sulfate; Trice-teareth-4 phosphate; glyceryl stearate; sodium cetylstearyl; lecithin; Trilaureth-4 phosphate; Laureth-4 phosphate; stearic acid; Propylene glycol stearate SE; PEG-25 hydrogenated castor oil; PEG-54 hydrogenated castor oil; PEG-6 caprylic acid / capric acid glycerides; sorbitan; Glyceryl oleate in a mixture with propylene glycol; PEG-9 stearate; Glyceryllanotat; Cet ⁇ th-2; Ceteth-20; Polysorbate
  • the aqueous phase of the preparations according to the invention advantageously advantageously contains alcohols, diols or polyols of low C number, and also their ethers, preferably ethanol, isopropanol, propylene glycol, glycerol, ethylene glycol, ethylene glycol monoethyl or - monobutyl ether, propylene glycol monomethyl, monoethyl or - onobutyl ether , Diethy- glycol monomethyl or monoethyl ether and analog products, furthermore alcohols of low C number, for example Ethanol, isopropanol, 1, 2-propanediol, glycerol and in particular one or more thickeners, which one or more can advantageously be selected from the group consisting of silicon dioxide, aluminum silicates, polysaccharides or their derivatives, e.g.
  • Hyaluronic acid, xanthan gum, hydroxypropylmethyl cellulose particularly advantageously from the group of polyacrylates, preferably a polyacrylate from the group of so-called carbopoles, for example carbopoles of types 980, 981, 1382, 2984, 5984, each individually or in combination.
  • Water can also be a component of alcoholic solvents.
  • Emulsions according to the invention are advantageous and contain, for example, the fats, oils, waxes and other fat bodies mentioned, as well as water and an emulsifier, as is customarily used for such a type of formulation.
  • Gels according to the invention usually contain alcohols of low C number, for example ethanol, isopropanol, 1, 2-propanediol, glycerol and water or an oil mentioned above in the presence of a thickening agent which, in the case of oily alcoholic gels, preferably silicon dioxide or an aluminum silicate is preferably a polyacrylate in the case of aqueous-alcoholic or alcoholic gels.
  • Suitable propellants for preparations according to the invention which can be sprayed from aerosol containers are the customary, known volatile, liquefied propellants, for example hydrocarbons (propane, butane, isobutane), which can be used alone or in a mixture with one another. Compressed air can also be used advantageously.
  • hydrocarbons propane, butane, isobutane
  • Preparations according to the invention can also advantageously contain substances which absorb UV radiation in the UVB range, the total amount of filter substances e.g. 0.1% by weight to 30% by weight, preferably 0.5 to 10% by weight, in particular 1.0 to 6.0% by weight, based on the total weight of the preparations, in order to prepare cosmetic preparations To provide that protect the hair or skin from the entire range of ultraviolet radiation. They can also serve as a sunscreen for the hair or skin.
  • UVB filter substances if they contain UVB filter substances, they can be oil-soluble or water-soluble.
  • Oil-soluble UVB filters which are advantageous according to the invention are, for example:
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably 4- (dimethylamino) benzoic acid (2-ethylhexyl) ester, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • esters of salicylic acid preferably salicylic acid (2-ethylhexyl) ester, salicylic acid (4-isopropylbenzyl) ester, salicylic acid homomethyl ester,
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone;
  • Esters of benzalmalonic acid preferably 4-methoxybenzalmalonic acid di (2-ethylhexyl) ester,
  • Triethanolammonium salt as well as the sulfonic acid itself
  • Sulfonic acid derivatives of benzophenones preferably 2-hydroxy-4-methoxybenzophenone-5-sulfonic acid and its salts;
  • UVB filters which can be used in combination with the active compound combinations according to the invention, is of course not intended to be limiting.
  • the invention also relates to the use of a combination of the active compound combinations used according to the invention with at least one UVB filter as an antioxidant or the use of a combination of the active compound combinations used according to the invention with at least one UVB filter as an antioxidant in a cosmetic or dermatological preparation.
  • UVA filters which have hitherto usually been contained in cosmetic preparations.
  • These substances are preferably derivatives of di-benzoylmethane, in particular 1- (4'-tert-butylphenyl) -3- (4'-methoxyphenyl) propane-1,3-dione and 1-phenyl-3- (4'-isopropylphenyl) propane-1,3-dione.
  • These combinations or preparations containing these combinations are also the subject of the invention.
  • the quantities used for the UVB combination can be used.
  • the invention also relates to the use of a combination of active ingredient combinations according to the invention with at least one UVA filter as an antioxidant or the use of a combination of the active ingredient combinations according to the invention with at least one UVA filter as an antioxidant in a cosmetic or dermatological preparation.
  • the invention also relates to the use of a combination of active compound combinations used according to the invention with at least one UVA filter and at least one UVB filter as an antioxidant or the use of a combination of active compound combinations with at least one UVA filter and at least one UVB filter as an antioxidant in a cosmetic or dermatological preparation.
  • Cosmetic and dermatological preparations with an effective content of active ingredient combinations used according to the invention can also contain inorganic pigments which are usually used in cosmetics to protect the skin from UV rays. These are oxides of titanium, zinc, zirconium, silicon, manganese, cerium and mixtures thereof, as well as modifications in which the oxides are the active agents. It is particularly preferred to use pigments based on titanium dioxide.
  • the cosmetic and dermatological agents contain active ingredients and auxiliaries, as are usually used for this type of preparations for hair care and hair treatment.
  • auxiliaries include preservatives, surface-active substances, substances to prevent foaming, thickeners, emulsifiers, fats, oils, waxes, organic solvents, bactericides, perfumes, dyes or pigments, the task of which is to add hair or the cosmetic or dermatological preparation itself to dye.
  • the anions according to the invention are preferably selected from the group consisting of the chlorides, the sulfates and hydrogen sulfates, the phosphates, hydrogen phosphates and the linear and cyclic oligophosphates as well as the carbonates and hydrogen carbonates.
  • Cosmetic preparations which are a skin cleansing agent or shampooing agent preferably contain at least one anionic, non-ionic or amphoteric surface-active substance, or else mixtures of such substances, the active substance combinations according to the invention in the aqueous medium and auxiliaries, as are usually used therefor.
  • the surface-active substance or the mixtures of these substances can be present in the shampoo in a concentration of between 1% and 50% by weight.
  • aqueous or aqueous-alcoholic solutions which may contain surface-active substances, the concentration of which is between 0.1 and 10% by weight, preferably between 0.2 and 5% by weight.
  • These cosmetic or dermatological preparations can also be aerosols with the auxiliaries usually used for them.
  • a cosmetic preparation in the form of a lotion that is not rinsed out, in particular a lotion for inlaying the hair, a lotion used for blow-drying the hair, a styling and treatment lotion generally provides an aqueous, alcoholic or aqueous-alcoholic solution represents and contains at least one cationic, anionic, non-ionic or amphoteric polymer or mixtures thereof, as well as active ingredient combinations used according to the invention in effective concentration.
  • the amount of the polymers used is e.g. between 0.1 and 10% by weight, preferably between 0.1 and 3% by weight.
  • Cosmetic preparations for the treatment and care of the hair which contain the active compound combinations used according to the invention, can be present as emulsions which are of the non-ionic or anionic type.
  • non-ionic emulsions contain oils or fatty alcohols, which can also be polyethoxylated or polypropoxylated, for example, or also mixtures of the two organic components.
  • These emulsions may contain cationic surface-active substances.
  • cosmetic preparations for the treatment and care of the hair can be in the form of gels which, in addition to an effective content of active ingredients according to the invention and, if appropriate, solvents conventionally used for this, preferably water, or organic thickeners, for example gum arabic, xanthan gum, sodium malginate, cellulose derivatives, are preferred Methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thickeners, for example aluminum silicates such as bentonites, or a mixture of polyethylene glycol and polyethylene glycol stearate or distearate.
  • solvents conventionally used for this, preferably water, or organic thickeners, for example gum arabic, xanthan gum, sodium malginate, cellulose derivatives, are preferred Methyl cellulose, hydroxymethyl cellulose, hydroxyethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose or inorganic thicken
  • the thickener is contained in the gel, for example, in an amount between 0.1 and 30% by weight, preferably between 0.5 and 15% by weight.
  • the amount of active compounds according to the invention in an agent intended for the hair is preferably 0.05% by weight to 10% by weight, in particular 0.5% by weight to 5% by weight, based on the total weight of the agent.
  • Aqueous cosmetic cleaning agents according to the invention or water-free or water-free cleaning agent concentrates intended for aqueous cleaning can contain anionic, nonionic and / or amphoteric surfactants.
  • Surfactants are amphiphilic substances that can dissolve organic, non-polar substances in water. Due to their specific molecular structure with at least one hydrophilic and one hydrophobic part of the molecule, they ensure a reduction in the surface tension of the water, wetting of the skin, facilitating dirt removal and removal, easy rinsing and, if desired, foam regulation.
  • hydrophilic parts of a surfactant molecule are mostly polar functional groups, for example -COO ' , -OSO 3 2 " , -SO 3 " , while the hydrophobic parts generally represent non-polar hydrocarbon radicals.
  • Surfactants are generally classified according to the type and charge of the hydrophilic part of the molecule. There are four groups:
  • Anionic surfactants generally have carboxylate, sulfate or sulfonate groups as functional groups. In an aqueous solution they form negatively charged organic ions in an acidic or neutral environment. Cationic surfactants are characterized almost exclusively by the presence of a quaternary ammonium group. In aqueous solution they form positively charged organic ions in an acidic or neutral environment. Amphoteric surfactants contain both anionic and cationic groups and accordingly behave like anionic or cationic surfactants in aqueous solution depending on the pH. They are positive in a strongly acidic environment and negative in an alkaline environment. fertil. In the neutral pH range, however, they are zwitterionic, as the following example should illustrate:
  • B + any cation, eg Na +
  • Non-ionic surfactants do not form ions in an aqueous medium.
  • acylglutamates for example sodium acylglutamate, di-TEA-palmitoylaspartate and sodium caprylic / capric glutamate,
  • acyl peptides for example palmitoyl-hydrolyzed milk protein, sodium cocoyl-hydrolyzed soy protein and sodium / potassium-cocoyl-hydrolyzed collagen,
  • sarcosinates for example myristoyl sarcosin, TEA-lauroyl sarcosinate, sodium lauroyl sarcosinate and sodium cocoyl sarcosinate,
  • taurates for example sodium lauroyl taurate and sodium methyl cocoyl taurate
  • carboxylic acids for example lauric acid, aluminum stearate, magnesium alkanolate and zinc undecylenate,
  • ester carboxylic acids for example calcium stearoyl lactylate, laureth-6-citrate and sodium PEG-4-lauramide carboxylate,
  • ether carboxylic acids for example sodium laureth-13 carboxylate and sodium PEG-6 cocamide carboxylate,
  • Phosphoric acid esters and salts such as DEA-oleth-10-phosphate and dilaureth-4-phosphate, Sulfonic acids and salts such as
  • acyl isethionates e.g. Sodium / ammonium cocoyl isethionate
  • alkyl sulfonates for example sodium cocosmonoglyceride sulfate, sodium C 12 . 1 olefin sulfonate, sodium lauryl sulfate acetate and magnesium PEG-3 cocamide sulfate,
  • Sulfosuccinates for example dioctyl sodium sulfosuccinate, disodium laureth sulfosuccinate, disodium lauryl sulfosuccinate and disodium undecylenamido MEA sulfosuccinate
  • sulfuric acid esters such as
  • alkyl ether sulfate for example sodium, ammonium, magnesium, MIPA, TIPA laureth sulfate, sodium myreth sulfate and sodium C 12- 3 pareth sulfate,
  • Alkyl sulfates for example sodium, ammonium and TEA lauryl sulfate.
  • Quaternary surfactants contain at least one N atom which is covalently linked to 4 alkyl and / or aryl groups. Regardless of the pH value, this leads to a positive charge.
  • Advantageous quaternary surfactants are alkyl betaine, alkyl amidopropyl betaine and alkyl amidopropyl hydroxysulfain.
  • Cationic surfactants can also preferred according to the present invention are selected from the group of quaternary ammonium compounds, especially benzyltrialkylammonium chlorides or bromides, for example benzyldimethylstearylammonium chloride, also alkyltrialkylammonium, for example cetyltrimethylammonium chloride or bromide, moniumchloride Alkyldimethylhydroxyethylam- or bromides, dialkyldimethylammonium chlorides or bromides , Alkylamidethyltrimethylammoniumethersulfate, Alkylpyridiniumsaize, for example lauryl or cetylpyrimidinium chloride, imidazoline derivatives and compounds with a cationic character such as amine oxides, for example alkyldimethylamine oxides or alkylaminoethyldimethylamino oxides. Cetyltrimethylammonium salts are particularly advantageous.
  • acyl- / dialkylethylenediamine for example sodium acylamphoacetate, disodium acylamphodipropionate, disodium alkylamphodiacetate, sodium acylamphohydroxypropylsulfonate, disodium acylamphodiacetate and sodium acylamphopropionate,
  • N-alkylamino acids for example aminopropylalkylglutamide, alkylaminopropionic acid, sodium alkylimidodipropionate and lauroamphocarboxyglycinate.
  • alkanolamides such as Cocamide MEA / DEA / MIPA
  • amine oxides such as cocoamidopropylamine oxide
  • esters which are formed by esterification of carboxylic acids with ethylene oxide, glycerol, sorbitan or other alcohols,
  • ethers for example ethoxylated / propoxylated alcohols, ethoxylated / propoxylated esters, ethoxylated / propoxylated glycerol esters, ethoxylated / propoxylated cholesterol, ethoxylated / propoxylated triglyceride esters, ethoxylated propoxylated lanolin, ethoxylated / propoxylated polysiloxanes, propoxylated POE ethers and alkylpolyglycols Lauryl glucoside, decyl glycoside and cocoglycoside.
  • Cosmetic preparations which are cosmetic cleaning preparations for the skin, can be in liquid or solid form.
  • they preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof and auxiliaries. tel, as they are usually used for this.
  • the surface-active substance can be present in the cleaning preparations in a concentration between 1 and 94% by weight, based on the total weight of the preparations.
  • cosmetic preparations which are a shampooing agent preferably contain at least one anionic, nonionic or amphoteric surface-active substance or mixtures thereof, and auxiliaries as are usually used therefor.
  • the surface-active substance can be present in the shampoo in a concentration between 1% by weight and 94% by weight.
  • compositions according to the invention contain water and, if appropriate, the additives customary in cosmetics, for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active substances and the like.
  • the additives customary in cosmetics for example perfume, thickeners, dyes, deodorants, antimicrobial substances, lipid-replenishing agents, complexing and sequestering agents, pearlescent agents, plant extracts, vitamins, active substances and the like.
  • Complexing agents are known auxiliaries in cosmetology and medical galenics.
  • the complexation of interfering metals such as Mn, Fe, Cu and others can, for example, prevent undesirable chemical reactions in cosmetic or dermatological preparations.
  • Complexing agents form complexes with metal atoms which, if one or more polybasic complexing agents, ie chelators, are metalacycles.
  • Chelates are compounds in which a single ligand occupies more than one coordination site on a central atom. In this case, normally elongated connections are closed to form rings by complex formation via a metal atom or ion. The number of ligands bound depends on the coordination number of the central metal. The prerequisite for chelation is that the compound reacting with the metal contains two or more atom groups which act as electron donors.
  • the complexing agent (s) can advantageously be selected from the group of the usual compounds, preferably at least one substance from the group consisting of tartaric acid and its anions, citric acid and its anions, aminopolycarbonic acids and their anions (such as, for example, ethylenediaminetetraacetic acid (EDTA) and their Anions, nitrilotriacetic acid (NTA) and their anions, hydroxyethylenediaminotriesacetic acid (HOEDTA) and their anions, diethylenaminopentaacetic acid (DPTA) and their anions, trans-1, 2-diaminocyclohexanetetraacetic acid (CDTA) and their anions).
  • EDTA ethylenediaminetetraacetic acid
  • NTA nitrilotriacetic acid
  • HOEDTA hydroxyethylenediaminotriesacetic acid
  • DPTA diethylenaminopentaacetic acid
  • CDTA 2-diamino
  • the complexing agent or complexing agents are advantageous in cosmetic or dermatological preparations, preferably at 0.01% by weight to 10% by weight, preferably at 0.05% by weight to 5% by weight, particularly preferably at 0.1 - 2.0 wt .-%, based on the total weight of the preparations.
  • the present invention also includes a method for protecting cosmetic or dermatological preparations against oxidation or photooxidation, these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can cause stability problems due to oxidation or photooxidation during storage, characterized in that the cosmetic preparations have an effective content of active ingredient combinations used according to the invention.
  • these preparations being e.g. Represent preparations for the treatment and care of the hair, in particular hair colorants, hair lacquers, shampooing agents, color shampooing agents, and also make-up products such as e.g. Nail polishes, lipsticks, complexion bases, washing and shower preparations, creams for the treatment or care of the skin or all other cosmetic preparations, the components of which can
  • the amount of active compound combinations used according to the invention in these preparations is preferably 0.01-30% by weight, preferably 0.05-20% by weight, in particular 0.1-10.0% by weight, based on the total weight of the preparations.
  • the invention also relates to the process for the preparation of the cosmetic compositions according to the invention, which is characterized in that active ingredient combinations according to the invention are incorporated into cosmetic and dermatological formulations in a manner known per se.
  • the components of the oil phase are combined with one another, then stirred at 60-70 ° C. with the likewise combined water phase, whereupon the mixture is homogenized. Then it is cooled to room temperature.
  • the components of the oil phase are combined with one another, then stirred at 60-70 ° C. with the likewise combined water phase, whereupon the mixture is homogenized. Then it is cooled to room temperature.
  • the components of the oil phase are combined with one another, then stirred at 60-70 ° C. with the likewise combined water phase, whereupon the mixture is homogenized. Then it is cooled to room temperature.
  • the components of the oil phase are combined with one another, then stirred at 60-70 ° C. with the likewise combined water phase, whereupon the mixture is homogenized. Then it is cooled to room temperature.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne l'utilisation d'électrolytes pour élaborer des préparations cosmétiques ou dermatologiques servant à traiter et à prévenir les problèmes de peau sèche ainsi que l'utilisation d'électrolytes pour élaborer des préparations cosmétiques et dermatologiques servant à traiter et à prévenir les problèmes de peau sèche ainsi qu'à renforcer la fonction barrière de la peau.
EP02743014A 2001-05-16 2002-05-15 Utilisation d'electrolytes pour renforcer la fonction barriere de la peau Ceased EP1392231A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09004241.7A EP2090283B1 (fr) 2001-05-16 2002-05-15 Utilisation d'électrolytes destinés au renforcement de la fonction de barrière de la peau

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10123771.5A DE10123771B4 (de) 2001-05-16 2001-05-16 Verwendung von Elektrolyten zur Stärkung der Barrierefunktion der Haut
DE10123771 2001-05-16
PCT/EP2002/005344 WO2002092044A2 (fr) 2001-05-16 2002-05-15 Utilisation d'electrolytes pour renforcer la fonction barriere de la peau

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP09004241.7A Division EP2090283B1 (fr) 2001-05-16 2002-05-15 Utilisation d'électrolytes destinés au renforcement de la fonction de barrière de la peau

Publications (1)

Publication Number Publication Date
EP1392231A2 true EP1392231A2 (fr) 2004-03-03

Family

ID=7684962

Family Applications (2)

Application Number Title Priority Date Filing Date
EP09004241.7A Revoked EP2090283B1 (fr) 2001-05-16 2002-05-15 Utilisation d'électrolytes destinés au renforcement de la fonction de barrière de la peau
EP02743014A Ceased EP1392231A2 (fr) 2001-05-16 2002-05-15 Utilisation d'electrolytes pour renforcer la fonction barriere de la peau

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP09004241.7A Revoked EP2090283B1 (fr) 2001-05-16 2002-05-15 Utilisation d'électrolytes destinés au renforcement de la fonction de barrière de la peau

Country Status (6)

Country Link
US (1) US20040197354A1 (fr)
EP (2) EP2090283B1 (fr)
JP (1) JP2005503347A (fr)
DE (1) DE10123771B4 (fr)
ES (1) ES2421380T3 (fr)
WO (1) WO2002092044A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10133201A1 (de) * 2001-07-07 2003-01-23 Beiersdorf Ag Elektrolythaltige kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der Haut
KR20170102377A (ko) 2004-01-22 2017-09-08 유니버시티 오브 마이애미 국소용 코-엔자임 큐10 제형 및 그의 사용 방법
BRPI0809164B8 (pt) 2007-03-22 2023-02-28 Berg Llc Composição para administração tópica e composição farmacêutica compreendendo a referida composição
US20090258085A1 (en) * 2008-03-17 2009-10-15 Ahava- Dead Sea Laboratories Ltd. Emulsions and methods of their production
WO2009126764A1 (fr) 2008-04-11 2009-10-15 Cytotech Labs, Llc Procédés et utilisation d'induction de l'apoptose dans des cellules cancéreuses
AT507845B1 (de) * 2009-02-12 2012-05-15 Lengheim Hubert Kosmetische zubereitung zur hautpflege
WO2010132502A2 (fr) 2009-05-11 2010-11-18 Cytotech Labs, Llc Méthodes de traitement de troubles métaboliques à l'aide de décaleurs épimétaboliques, de molécules intracellulaires multidimensionnelles ou d'influenceurs environnementaux
WO2011112900A2 (fr) 2010-03-12 2011-09-15 Cytotech Labs, Llc Formulations intraveineuses de coenzyme q10 (coq10) et leurs procédés d'utilisation
AU2012240222B2 (en) 2011-04-04 2017-04-27 Berg Llc Methods of treating central nervous system tumors
EA201490047A1 (ru) 2011-06-17 2014-08-29 Берг Ллк Ингаляционные фармацевтические композиции
US10933032B2 (en) 2013-04-08 2021-03-02 Berg Llc Methods for the treatment of cancer using coenzyme Q10 combination therapies
EP3730131A1 (fr) 2013-09-04 2020-10-28 Berg LLC Procédés de traitement du cancer par perfusion continue de coenzyme q10
KR102097265B1 (ko) * 2019-09-02 2020-04-06 코스맥스 주식회사 전해물질을 포함하는 보습 및 피부장벽 개선용 화장료 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6216409A (ja) * 1985-07-13 1987-01-24 Kinkai Engiyou Kk 塩化ナトリウム入り美容剤
ATE69954T1 (de) * 1985-10-08 1991-12-15 Psori Med Ag Salzmischung zur behandlung der schuppenflechte (psoriasis) und anderer hautkrankheiten.
DE3905299C1 (fr) * 1989-02-21 1990-08-09 Peter Prof. Dr.Med. 7980 Ravensburg De Klein
GB8927703D0 (en) * 1989-12-07 1990-02-07 Unilever Plc Cosmetic composition
DE4201694C2 (de) * 1991-02-06 1994-11-10 Beiersdorf Ag Stabile kosmetische Mittel
JPH0742211B2 (ja) * 1992-01-31 1995-05-10 忠 鄭 水性皮膚及び頭皮・頭髪化粧料
DE4304066C2 (de) 1993-02-11 1995-01-26 Beiersdorf Ag Verwendung von hohen Elektrolytkonzentrationen in kosmetischen Reinigungsmitteln
AU2456097A (en) * 1996-05-21 1997-12-09 Dermasciences, Inc. Topical barrier composition containing silicone and bentonite
US6197317B1 (en) * 1997-08-11 2001-03-06 Marvin E. Klein Composition and method for the treatment of skin
EP0937453A3 (fr) * 1998-01-26 2000-04-19 Sam Schwartz Composition cosmétique, lavante et/ou humidifiante
DE19857490A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Hautschutzpräparate zur Prävention von Hautschäden
DE19857492A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Wasserhaltige Hautschutzpräparate zur Prävention von Hautschäden
DE19857491A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Hautschutzpräparate zur Prävention von Hautschäden mit UV-Filtern
DE19857489A1 (de) * 1998-12-14 2000-06-15 Hans Lautenschlaeger Ölhaltige Hautschutzpräparate zur Prävention von Hautschäden
EP1074245A3 (fr) * 1999-08-06 2001-05-30 Sam Schwartz Composition avec des sels minéraux pour un traitement thérapeutique
JP3559507B2 (ja) * 2000-08-03 2004-09-02 ワミレスコスメティックス株式会社 化粧料

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02092044A3 *

Also Published As

Publication number Publication date
JP2005503347A (ja) 2005-02-03
US20040197354A1 (en) 2004-10-07
ES2421380T3 (es) 2013-09-02
WO2002092044A3 (fr) 2003-12-11
WO2002092044A2 (fr) 2002-11-21
EP2090283A1 (fr) 2009-08-19
DE10123771A1 (de) 2002-11-21
DE10123771B4 (de) 2019-01-10
EP2090283B1 (fr) 2013-04-17

Similar Documents

Publication Publication Date Title
EP1406599B1 (fr) Preparations cosmetiques et dermatologiques a la creatine utilisees dans le traitement et la prevention active de la peau seche et d'autres modifications negatives de l'homeostase physiologique des peaux saines
EP1406588A2 (fr) Preparations cosmetiques et dermatologiques contenant des osmolytes destinees au traitement et a la prevention active de la secheresse cutanee et d'autres modifications negatives de l'homeostasie physiologique de la peau saine
WO2002000185A1 (fr) Utilisation de substances liberant ou liant le calcium pour diminuer ou renforcer de maniere ciblee la fonction de barriere de la peau
EP2090283B1 (fr) Utilisation d'électrolytes destinés au renforcement de la fonction de barrière de la peau
WO2003009825A2 (fr) Preparations cosmetiques et dermatologiques contenant des catechines ou extraits de the vert pour le traitement et la prevention active des peaux seches et d'autres modifications negatives de l'homeostasie physiologique des peaux saines
WO2003005980A2 (fr) Preparations cosmetiques et dermatologiques contenant de la carnitine pour le traitement et la prevention active de la peau seche et autres alterations negatives de l'homeostasie physiologique de la peau saine
WO2000007557A1 (fr) Preparations cosmetiques et dermatologiques presentant une quantite efficace d'acides biliaires, de leurs sels et/ou de leurs derives
EP0995430A2 (fr) Utilisation de diacylglycérols pour renforcer la fonction de barrière de la peau
WO2003037277A1 (fr) Preparations cosmetiques et dermatologiques contenant de la glycerine sur la base d'emulsions huile dans eau
DE10133197A1 (de) Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133196A1 (de) Nicotinsäure enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE19962267A1 (de) Verwendung von Wirkstoffkombinationen aus einem oder mehreren NO-Synthasehemmern und einer oder mehreren Ascorbylverbindungen zur Stärkung der Barrierefunktion der Haut
WO2003007892A2 (fr) Preparations cosmetiques et dermatologiques contenant un electrolyte pour le traitement et la prevention active de la peau seche et d'autres modifications negatives de l'homeostase de la peau
DE10133195A1 (de) Biotin enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE10133199A1 (de) Cineol enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut
DE19918761A1 (de) Kosmetische Zubereitungen mit einem Gehalt an 5-Hydroxy-3-methyl-2-pentensäure-1,5-lacton sowie die Verwendung von 5-Hydroxy-3-methyl-2-pentensäure-1,5-lacton zur Stärkung der Barrierefunktion der Haut
EP1180358B1 (fr) Utilisation des acides gras insaturés et alcoxylés comme antitranspirants
DE10121093A1 (de) Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zur Verbesserung der Barrierefunktion der Haut
DE19834813A1 (de) Verwendung von Glycerin- und/oder Glykolestern langkettiger, aliphatischer, verzweigter und/oder unverzweigter Fettsäuren in kosmetischen und dermatologischen Zubereitungen zur Stärkung der Barrierefunktion der Haut
DE10121070A1 (de) Verwendung von Tetrahydrocurcuminoiden oder deren Derivaten als Wirkstoffe zur Herstellung von kosmetischen und dermatologischen Zubereitungen zur Anregung der Ceramid-Biosynthese der Haut
DE10204526A1 (de) Kosmetische und dermatologische Zubereitungen mit Eucalyptusöl in Kombination mit weiteren Wirk- und Inhaltsstoffen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SCHREINER, VOLKER

Inventor name: SIEFKEN, WILFRID

Inventor name: DOERING, THOMAS

Inventor name: SAUERMANN, GERHARD

Inventor name: BIERGIESSER, HELGA

17P Request for examination filed

Effective date: 20040611

R17C First examination report despatched (corrected)

Effective date: 20061222

APBK Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNE

APBN Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2E

APAF Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNE

APBT Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9E

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20090409